Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Idorsia Pharmaceuticals Ltd. Clear all
Completed Phase 3 Interventional Results available

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

NCT03585270
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

NCT03869320
View directory record Official record
Conditions
Healthy
Interventions
ACT-1004-1239, Placebo, ACT-1004-1239 (Food-effect subpart), Placebo (Food-effect subpart)
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 7, 2026, 3:38 PM EDT
Active, not recruiting No phase listed Observational

Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

NCT06393504
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Daridorexant, Non-orexin receptor antagonist insomnia medication, No insomnia medication
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
2,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

NCT03056053
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Santa Monica, California • Atlanta, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 7, 2026, 3:38 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

NCT02841761
View directory record Official record
Conditions
Healthy Subjects
Interventions
Midalozam, Aprocitentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

NCT03545191
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
36
States / cities
Anniston, Alabama • Birmingham, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

NCT03679884
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 7, 2026, 3:38 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

NCT05948540
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention C Daridorexant, Intervention C Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 7, 2026, 3:38 PM EDT
Terminated Phase 2 Interventional

Tezosentan in Pulmonary Arterial Hypertension

NCT01077297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 7, 2026, 3:38 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

NCT06816433
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 7, 2026, 3:38 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214
View directory record Official record
Conditions
Fabry Disease
Interventions
Lucerastat
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Irvine, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

NCT01225315
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Setipiprant
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Los Angeles, California • Tallahassee, Florida • Normal, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

NCT03657355
View directory record Official record
Conditions
Healthy Recreational Drug Users
Interventions
ACT-541468, Suvorexant, Zolpidem, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 3 Interventional

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

NCT00558311
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
11
States / cities
Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

NCT03586570
View directory record Official record
Conditions
Healthy Subjects
Interventions
Aprocitentan 25mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 7, 2026, 3:38 PM EDT
Terminated Phase 2 Interventional

Tezosentan in Patients With Pulmonary Arterial Hypertension

NCT01094067
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ACT-050089, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 7, 2026, 3:38 PM EDT
Not yet recruiting No phase listed Observational

IMPACT-HTN Study of Patients With Hypertension

NCT07579260
View directory record Official record
Conditions
Hypertension (HTN), Hypertension, Blood Pressure, High
Interventions
Not listed
Lead sponsor
Vivek Bhalla
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

NCT01241214
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
ACT-129968, Cetirizine, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Not applicable Interventional

Sleep in Collegiate Baseball Players

NCT07212101
View directory record Official record
Conditions
Sleep
Interventions
Sleep and diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 3 Interventional

Tezosentan in the Treatment of Acute Heart Failure

NCT00524433
View directory record Official record
Conditions
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
Interventions
tezosentan, placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
16
States / cities
Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 7, 2026, 3:38 PM EDT
Completed No phase listed Observational

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2

NCT04470713
View directory record Official record
Conditions
GM1 Gangliosidosis, GM2 Gangliosidosis, Gaucher Disease, Type 2, Tay-Sachs Disease, AB Variant Gangliosidosis GM2, Sandhoff Disease
Interventions
Not listed
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
0 Months and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

NCT05597020
View directory record Official record
Conditions
Insomnia Disorder, Nocturia
Interventions
Daridorexant, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Miami Beach, Florida • Pompano Beach, Florida • Weston, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 7, 2026, 3:38 PM EDT
Completed Phase 3 Interventional

Tezosentan in Acute Heart Failure

NCT00525707
View directory record Official record
Conditions
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
Interventions
tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 7, 2026, 3:38 PM EDT